Table 1 Baseline Characteristics and Medication Use of the Study Population.
Oat used | p Value | ||
|---|---|---|---|
No (n = 474) | Yes (n = 242) | ||
Age, years | 65.26 ± 12.19 | 68.82 ± 11.65 | 0.0002 |
Male, n (%) | 408 (86.08) | 202 (83.47%) | 0.353 |
Hypertension, n (%) | 306 (64.56) | 160 (66.12%) | 0.679 |
Diabetes, n (%) | 178 (37.55) | 86 (35.54%) | 0.597 |
Smoking, n (%) | 269 (56.75) | 117 (48.35%) | 0.033 |
History of CAD, n (%) | 117 (24.68) | 60 (24.79%) | 0.974 |
History of stroke, n (%) | 11 (2.32) | 5 (2.07%) | 0.827 |
BMI, kg/m2 | 26.47 ± 5.24 | 25.92 ± 3.65 | 0.1005 |
Waist, cm | 94.21 ± 10.23 | 93.34 ± 9.07 | 0.2438 |
Buttocks, cm | 99.11 ± 8.43 | 99.9 ± 9.28 | 0.2523 |
Waist to hip ratio | 0.95 ± 0.08 | 0.94 ± 0.07 | 0.0067 |
Systolic BP, mmHg | 129.58 ± 17.93 | 129.3 ± 15.53 | 0.8297 |
Diastolic BP, mmHg | 74.01 ± 12.36 | 72.58 ± 12.14 | 0.1394 |
Stenosis vessel, n (%) | 2.01 ± 0.92 | 2.03 ± 0.94 | 0.8468 |
Stenosis lesion, n (%) | 3.31 ± 2.21 | 3.27 ± 2 | 0.8382 |
Stenting, n (%) | 1.56 ± 0.93 | 1.62 ± 0.87 | 0.4966 |
LVEF (%) | 57.05 ± 12.36 | 56.17 ± 12.74 | 0.483 |
Medication | |||
Anti-platelet, n (%) | 427 (90.0) | 226 (93.4) | 0.14 |
Aspirin, n (%) | 345 (72.7) | 188 (77.6) | 0.155 |
clopidogrel, n (%) | 223 (47.0) | 117 (48.3) | 0.742 |
Anticoagulant, n (%) | 11 (2.3) | 8 (3.3) | 0.438 |
ACE inhibitor, n (%) | 106 (22.3) | 55 (22.7) | 0.912 |
ARB, n (%) | 208 (43.8) | 106 (43.8) | 0.984 |
Beta-blocker, n (%) | 285 (60.1) | 137 (56.6) | 0.366 |
CCB, n (%) | 211 (44.5) | 112 (46.2) | 0.653 |
CCB, DHP, n (%) | 163 (34.3) | 94 (38.8) | 0.240 |
Diuretics, n (%) | 62 (13.0) | 29 (11.9) | 0.677 |
Nitrate, n (%) | 233 (49.1) | 128 (52.8) | 0.344 |
Statin, n (%) | 333 (70.2) | 172 (71.1) | 0.820 |
PPIs, n (%) | 20 (4.2) | 10 (4.1) | 0.956 |
